The All Wales Medicines Strategy Group (AWMSG) has launched a consultation to establish how products can be classed as low value, providing a method to ‘disinvest’ from such products in future.
The consultation document, Delivering Value Through Disinvestment: An exploration and analysis of appropriate disinvestment in medicine considered Low Value for Funding by NHS Wales explains:
“The All Wales Medicines Strategy Group (AWMSG) has a 5-year strategy to support the best use of medicines within NHS Wales to improve outcomes for people taking them. One recommendation in the strategy is to develop an evidence-based approach to decide whether to stop prescribing certain medicines in NHS Wales if they are considered as low-value for prescribing (LVP).”
The paper aims to establish the framework under which LVPs can be identified and then deprioritised for use in NHS Wales.
Read the consultation documentation for more information.